



Correction: SelectImmune Pharma AB to conduct clinical trials in cystitis and bladder pain syndrome

As of March 29th, SelectImmune Pharma AB has signed an agreement with Swedish Orphan Biovitrum (Sobi®) to buy Kineret® (anakinra) and placebo in order to investigate anakinra as a potential treatment of patients with select forms of cystitis and bladder pain syndrome.

Extensive research into the molecular mechanism of cystitis at Lund University has identified interleukin-1 alpha and beta as a major regulator of inflammation and disease in acute cystitis and bladder pain syndrome. The interleukin-1 alpha and beta receptor antagonist (IL1-RA) anakinra has been shown to inhibit inflammation and infection in animal models of cystitis and SelectImmune Pharma is now pursuing clinical trials to further assess the clinical efficacy in these areas.

Kineret (anakinra) is a trademark of Sobi, who markets the drug for various inflammatory conditions, whereas SelectImmune Pharma's patents cover the use of anakinra for the treatment of cystitis and bladder pain syndrome specifically.

The agreement defines that SelectImmune Pharma will conduct clinical trials in these areas with Sobi as the provider of drug and placebo. The parties have the intention to discuss a potential commercialization agreement for the indications protected by SelectImmune Pharma's patent rights.

"We are delighted to have the purchase agreement in place to be able to pursue the studies of the different clinical indications where anakinra has the potential to add value for patients," says Catharina Svanborg, Chairman, SelectImmune Pharma.

"This agreement is of great value to SelectImmune Pharma and we very much look forward to seeing the results of these studies" says Ann Gidner, CEO, SelectImmune Pharma.

For more information, please contact

Catharina Svanborg

Chairman

SelectImmune Pharma AB

Phone +46 709 42 65 49

catharina.svanborg@med.lu.se

Ann Gidner

CEO

SelectImmune Pharma AB

Phone +46 768 17 14 14

ann.gidner@selectImmune.com

This disclosure contains information that SelectImmune is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 29-03-2022 21:38 CET.

SelectImmune Pharma is a pharmaceutical company whose shares are traded on the Spotlight Stock Market. The company goal is to develop new immunotherapies, which act as immune enhancers and offer alternatives to antibiotics.

Bacterial infections affect large parts of the population and are becoming increasingly difficult to treat due to increasing antibiotic resistance. SelectImmune Pharma develops immunotherapies that can supplement or replace antibiotics. Urinary tract infections (UVI) are one of the world's most common infectious diseases, affecting about 150 million people each year. The need for alternative treatments for bacterial infections is currently very large as are potential markets.